These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 10792998)

  • 1. Synergistic interactions of antibodies in rate of virus neutralization.
    Sanna PP; Ramiro-Ibañez F; De Logu A
    Virology; 2000 May; 270(2):386-96. PubMed ID: 10792998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiviral effect of recombinant antibody to influenza virus HA antigen].
    Yang G; Wang Y; Zhao X; Han F; Wu S; Hou Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):337-40. PubMed ID: 12665899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different neutralization efficiency of neutralizing monoclonal antibodies against avian influenza H5N1 virus to virus strains from different hosts.
    Huang H; Dan H; Zhou Y; Yu Z; Fan H; Tong T; Jin M; Chen H
    Mol Immunol; 2007 Feb; 44(5):1052-5. PubMed ID: 16965815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies.
    Kawade Y; Watanabe Y
    Immunology; 1985 Nov; 56(3):489-95. PubMed ID: 4077097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.
    Wu H; Pfarr DS; Tang Y; An LL; Patel NK; Watkins JD; Huse WD; Kiener PA; Young JF
    J Mol Biol; 2005 Jul; 350(1):126-44. PubMed ID: 15907931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoclonal antibodies which recognize herpes simplex virus and their possible diagnostic application].
    Pupo Antúnez M; Hermida Díaz C; Morier Díaz L; García Infante S; Resik Aguirre S
    Rev Cubana Med Trop; 1997; 49(3):181-5. PubMed ID: 9685985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
    Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
    J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization kinetics of sensitive and resistant subtype B primary human immunodeficiency virus type 1 isolates.
    Davis D; Donners H; Willems B; Ntemgwa M; Vermoesen T; van der Groen G; Janssens W
    J Med Virol; 2006 Jul; 78(7):864-76. PubMed ID: 16721864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody and virus: binding and neutralization.
    Burton DR; Williamson RA; Parren PW
    Virology; 2000 Apr; 270(1):1-3. PubMed ID: 10772973
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies.
    Putnak JR; de la Barrera R; Burgess T; Pardo J; Dessy F; Gheysen D; Lobet Y; Green S; Endy TP; Thomas SJ; Eckels KH; Innis BL; Sun W
    Am J Trop Med Hyg; 2008 Jul; 79(1):115-22. PubMed ID: 18606774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective efficacy of neutralizing antibodies against Ebola virus infection.
    Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y
    Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
    Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
    Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic relationship between five isolates of murine gammaherpesvirus analysed with monoclonal antibodies.
    Matuskova M; Mistrikova J; Mrmusova M; Zilka N; Stancekova M; Kontsekova E
    Arch Virol; 2003 Jun; 148(6):1027-36. PubMed ID: 12756612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.
    Raviprakash K; Marques E; Ewing D; Lu Y; Phillips I; Porter KR; Kochel TJ; August TJ; Hayes CG; Murphy GS
    Virology; 2001 Nov; 290(1):74-82. PubMed ID: 11883007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.
    Sastre P; Melero JA; García-Barreno B; Palomo C
    Vaccine; 2004 Dec; 23(4):435-43. PubMed ID: 15530691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of animal virus infectivity by antibody.
    Reading SA; Dimmock NJ
    Arch Virol; 2007; 152(6):1047-59. PubMed ID: 17516034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute retinal necrosis six years after herpes simplex encephalitis: an elusive immune deficit suggested by insufficient test sensitivity.
    Preiser W; Doerr HW; Buxbaum S; Rabenau HF; Baatz H
    J Med Virol; 2004 Jun; 73(2):250-5. PubMed ID: 15122800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library.
    Lim AP; Chan CE; Wong SK; Chan AH; Ooi EE; Hanson BJ
    Virol J; 2008 Oct; 5():130. PubMed ID: 18957074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.
    Gros L; Dreja H; Fiser AL; Plays M; Pelegrin M; Piechaczyk M
    J Virol; 2005 May; 79(10):6272-80. PubMed ID: 15858011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.